Opendata, web and dolomites

BBDiag SIGNED

Blood Biomarker-based Diagnostic Tools for Early Stage Alzheimer’s Disease

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 BBDiag project word cloud

Explore the words cloud of the BBDiag project. It provides you a very rough idea of what is the project "BBDiag" about.

trial    cutting    point    uses    transferable    triple    notable    invasive    lack    establishes    synergies    tools    academia    innovative    met    failures    intervention    nature    intensive    blood    biosensing    innovatively    underlines    scientific    responds    imposed    million    personal    technological    preventive    societal    diagnostics    generation    trials    trained    edge    care    industrial    combined    setting    discovery    thinking    entrepreneurial    technologies    creative    double    13    first    despite    fellows    identification    business    framework    disease    successful    medical    platform    bbdiag    drug    quality    etn    alzheimer    efforts    biomarkers    industry    ad    techniques    skilled    clinical    gaining    academic    vitae    skills    treatments    provision    training    careers    detection    modifying    patients    mind    strategies    sensitive    stage    researcher    minimally    interdisciplinary    experts    brings    people    multidisciplinary    figure    expertise   

Project "BBDiag" data sheet

The following table provides information about the project.

Coordinator
UNIVERSITY OF PLYMOUTH 

Organization address
address: DRAKE CIRCUS
city: PLYMOUTH
postcode: PL4 8AA
website: www.plymouth.ac.uk

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country United Kingdom [UK]
 Project website http://bbdiag-itn-etn.eu/
 Total cost 3˙465˙708 €
 EC max contribution 3˙465˙708 € (100%)
 Programme 1. H2020-EU.1.3.1. (Fostering new skills by means of excellent initial training of researchers)
 Code Call H2020-MSCA-ITN-2016
 Funding Scheme MSCA-ITN-ETN
 Starting year 2017
 Duration (year-month-day) from 2017-01-01   to  2020-12-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    UNIVERSITY OF PLYMOUTH UK (PLYMOUTH) coordinator 819˙863.00
2    UNIVERSITA DEGLI STUDI DI ROMA LA SAPIENZA IT (ROMA) participant 516˙122.00
3    ISTITUTO DI RICERCHE FARMACOLOGICHE MARIO NEGRI IT (MILANO) participant 424˙439.00
4    DANMARKS TEKNISKE UNIVERSITET DK (KGS LYNGBY) participant 290˙081.00
5    NORDIC BIOSCIENCE A/S DK (HERLEV) participant 290˙081.00
6    PROGNOMICS LTD UK (SWANSEA) participant 273˙287.00
7    SWANSEA UNIVERSITY UK (SWANSEA) participant 273˙287.00
8    UNIVERSITATSMEDIZIN ROSTOCK DE (ROSTOCK) participant 249˙216.00
9    CENTRO DE INVESTIGACION BIOMEDICA EN RED ENFERMEDADES NEURODEGENERATIVAS ES (SEVILLA) participant 247˙872.00
10    ADVANCED MEDICAL PROJECTS SOCIEDAD LIMITADA ES (GUADALAJARA) participant 81˙453.00
11    NORDIC BIOSCIENCE COMPOUND DEVELOPMENT A/S DK (Helev) participant 0.00
12    China Capital Medical University CN (Beijing) partner 0.00
13    ENGAGE - KEY TECHNOLOGY VENTURES AG DE (KARLSRUHE) partner 0.00
14    HUNAN UNIVERSITY CN (CHANGSHA) partner 0.00
15    Re:Cognition Health Ltd. UK (London) partner 0.00

Map

 Project objective

Alzheimer’s disease (AD) affects more than 7 million people in Europe and this figure is expected to double every 20 years. Despite intensive efforts, no disease-modifying treatments or preventive strategies are available. The lack of specific, sensitive and minimally invasive diagnostics to identify people with early-stage AD to be included in clinical drug intervention trials is among the main reasons for many notable trial failures. The main challenges in developing the required diagnostics are identification of AD biomarkers and development of their detection techniques. The complex and interdisciplinary nature of the research underlines the need for innovative training of a new generation of researchers in the field. BBDiag responds to such a need and establishes a much-needed ETN for blood based early-AD diagnostics to address these challenges. It brings together leading academic and industrial experts from five major consortia in Europe and uses their synergies to build a triple-i research & training platform with the required multidisciplinary expertise and cutting-edge technologies. BBDiag Fellows will be trained under the Vitae Researcher Development Framework innovatively combined with the BBDiag platform for gaining interdisciplinary scientific and transferable skills as well as personal quality, creative thinking and business mind-set. The ETN has a highly innovative research programme for the discovery of AD biomarkers, development of novel biosensing techniques and point of care tools, and for technological exploitation of the diagnostics. These advances will strongly support improved care provision and development of disease-modifying treatments and preventive strategies for AD patients. More importantly, BBDiag will deliver its first generation of 13 highly-skilled, creative and entrepreneurial Fellows, setting them on a path to successful careers in academia or industry to ensure that the medical and societal challenges imposed by AD are met.

 Deliverables

List of deliverables.
Dissemination report Documents, reports 2019-09-18 10:55:32
Supervisory Board of the network Other 2019-09-18 10:55:31
Report on network training events & secondments Documents, reports 2019-09-18 10:55:31
Progress Report Documents, reports 2019-09-18 10:55:31

Take a look to the deliverables list in detail:  detailed list of BBDiag deliverables.

 Publications

year authors and title journal last update
List of publications.
2018 Stefan Teipel, Alexandra König, Jesse Hoey, Jeff Kaye, Frank Krüger, Julie M. Robillard, Thomas Kirste, Claudio Babiloni
Use of nonintrusive sensor-based information and communication technology for real-world evidence for clinical trials in dementia
published pages: 1216-1231, ISSN: 1552-5260, DOI: 10.1016/j.jalz.2018.05.003
Alzheimer\'s & Dementia 14/9 2019-09-18
2019 Claudio Babiloni, Claudio Del Percio, Roberta Lizio, Giuseppe Noce, Susanna Lopez, Andrea Soricelli, Raffaele Ferri, Maria Teresa Pascarelli, Valentina Catania, Flavio Nobili, Dario Arnaldi, Francesco Famà, Francesco Orzi, Carla Buttinelli, Franco Giubilei, Laura Bonanni, Raffaella Franciotti, Marco Onofrj, Paola Stirpe, Peter Fuhr, Ute Gschwandtner, Gerhard Ransmayr, Lucia Fraioli, Lucilla Parnetti, Lucia Farotti, Michela Pievani, Fabrizia D\'Antonio, Carlo De Lena, Bahar Güntekin, Lutfu Hanoğlu, Görsev Yener, Derya Durusu Emek-Savaş, Antonio Ivano Triggiani, John Paul Taylor, Ian McKeith, Fabrizio Stocchi, Laura Vacca, Giovanni B. Frisoni, Maria Francesca De Pandis
Levodopa may affect cortical excitability in Parkinson\'s disease patients with cognitive deficits as revealed by reduced activity of cortical sources of resting state electroencephalographic rhythms
published pages: 9-20, ISSN: 0197-4580, DOI: 10.1016/j.neurobiolaging.2018.08.010
Neurobiology of Aging 73 2019-09-18
2018 Moira Marizzoni, Clarissa Ferrari, Jorge Jovicich, Diego Albani, Claudio Babiloni, Libera Cavaliere, Mira Didic, Gianluigi Forloni, Samantha Galluzzi, Karl-Titus Hoffmann, José Luis Molinuevo, Flavio Nobili, Lucilla Parnetti, Pierre Payoux, Federica Ribaldi, Paolo Maria Rossini, Peter Schönknecht, Andrea Soricelli, Tilman Hensch, Magda Tsolaki, Pieter Jelle Visser, Jens Wiltfang, Jill C. Richardson, Régis Bordet, Olivier Blin, Giovanni B. Frisoni
Predicting and Tracking Short Term Disease Progression in Amnestic Mild Cognitive Impairment Patients with Prodromal Alzheimer’s Disease: Structural Brain Biomarkers
published pages: 1-12, ISSN: 1387-2877, DOI: 10.3233/jad-180152
Journal of Alzheimer\'s Disease 2019-09-18
2018 Claudio Babiloni, Claudio Del Percio, Roberta Lizio, Giuseppe Noce, Susanna Lopez, Andrea Soricelli, Raffaele Ferri, Maria Teresa Pascarelli, Valentina Catania, Flavio Nobili, Dario Arnaldi, Francesco Famà, Francesco Orzi, Carla Buttinelli, Franco Giubilei, Laura Bonanni, Raffaella Franciotti, Marco Onofrj, Paola Stirpe, Peter Fuhr, Ute Gschwandtner, Gerhard Ransmayr, Heinrich Garn, Lucia Fraioli, Michela Pievani, Fabrizia D\'Antonio, Carlo De Lena, Bahar Güntekin, Lutfu Hanoğlu, Erol Başar, Görsev Yener, Derya Durusu Emek-Savaş, Antonio Ivano Triggiani, John Paul Taylor, Maria Francesca De Pandis, Laura Vacca, Giovanni B. Frisoni, Fabrizio Stocchi
Functional cortical source connectivity of resting state electroencephalographic alpha rhythms shows similar abnormalities in patients with mild cognitive impairment due to Alzheimer’s and Parkinson’s diseases
published pages: 766-782, ISSN: 1388-2457, DOI: 10.1016/j.clinph.2018.01.009
Clinical Neurophysiology 129/4 2019-09-18
2018 Diego Albani, Moira Marizzoni, Clarissa Ferrari, Federica Fusco, Lucia Boeri, Ilaria Raimondi, Jorge Jovicich, Claudio Babiloni, Andrea Soricelli, Roberta Lizio, Samantha Galluzzi, Libera Cavaliere, Mira Didic, Peter Schönknecht, José Luis Molinuevo, Flavio Nobili, Lucilla Parnetti, Pierre Payoux, Luisella Bocchio, Marco Salvatore, Paolo Maria Rossini, Magda Tsolaki, Pieter Jelle Visser, Jill C. Richardson, Jens Wiltfang, Régis Bordet, Olivier Blin, Gianluigi Forloni, Giovanni B. Frisoni, PharmaCog Consortium
Plasma Aβ42 as Biomarker of Prodromal Alzheimer’s Disease Progression in Patients with Amnestic Mild Cognitive Impairment: Evidence from the PharmaCog/E-ADNI Study
published pages: 1-12, ISSN: 1387-2877, DOI: 10.3233/jad-180321
Journal of Alzheimer\'s Disease 2019-09-18
2018 Xinzhong Li, Haiyan Wang, Jintao Long, Genhua Pan, Taigang He, Oleg Anichtchik, Robert Belshaw, Diego Albani, Paul Edison, Elaine K Green, James Scott
Systematic Analysis and Biomarker Study for Alzheimer’s Disease
published pages: , ISSN: 2045-2322, DOI: 10.1038/s41598-018-35789-3
Scientific Reports 8/1 2019-09-18
2018 Claudio Babiloni, Claudio Del Percio, Roberta Lizio, Giuseppe Noce, Susanna Lopez, Andrea Soricelli, Raffaele Ferri, Flavio Nobili, Dario Arnaldi, Francesco Famà, Dag Aarsland, Francesco Orzi, Carla Buttinelli, Franco Giubilei, Marco Onofrj, Fabrizio Stocchi, Paola Stirpe, Peter Fuhr, Ute Gschwandtner, Gerhard Ransmayr, Heinrich Garn, Lucia Fraioli, Michela Pievani, Giovanni B. Frisoni, Fabrizia D\'Antonio, Carlo De Lena, Bahar Güntekin, Lutfu Hanoğlu, Erol Başar, Görsev Yener, Derya Durusu Emek-Savaş, Antonio Ivano Triggiani, Raffaella Franciotti, John Paul Taylor, Laura Vacca, Maria Francesca De Pandis, Laura Bonanni
Abnormalities of resting-state functional cortical connectivity in patients with dementia due to Alzheimer\'s and Lewy body diseases: an EEG study
published pages: 18-40, ISSN: 0197-4580, DOI: 10.1016/j.neurobiolaging.2017.12.023
Neurobiology of Aging 65 2019-09-18
2019 Michiel Van Bulck, Ana Sierra-Magro, Jesus Alarcon-Gil, Ana Perez-Castillo and Jose A. Morales-Garcia
Novel Approaches for the Treatment of Alzheimer’s and Parkinson’s Disease
published pages: 1044, ISSN: 1422-0067, DOI: 10.3390/ijms20030719
International Journal of Molecular Sciences 20/5 2019-09-18
2018 Harald Hampel, Nicola Toschi, Claudio Babiloni, Filippo Baldacci, Keith L. Black, Arun L.W. Bokde, René S. Bun, Francesco Cacciola, Enrica Cavedo, Patrizia A. Chiesa, Olivier Colliot, Cristina-Maria Coman, Bruno Dubois, Andrea Duggento, Stanley Durrleman, Maria-Teresa Ferretti, Nathalie George, Remy Genthon, Marie-Odile Habert, Karl Herholz, Yosef Koronyo, Maya Koronyo-Hamaoui, Foudil Lamari, Todd Langevin, Stéphane Lehéricy, Jean Lorenceau, Christian Neri, Robert Nisticò, Francis Nyasse-Messene, Craig Ritchie, Simone Rossi, Emiliano Santarnecchi, Olaf Sporns, Steven R. Verdooner, Andrea Vergallo, Nicolas Villain, Erfan Younesi, Francesco Garaci, Simone Lista
Revolution of Alzheimer Precision Neurology. Passageway of Systems Biology and Neurophysiology
published pages: S47-S105, ISSN: 1387-2877, DOI: 10.3233/jad-179932
Journal of Alzheimer\'s Disease 64/s1 2019-09-18
2018 Fatemah A. Sakr, Michel J. Grothe, Enrica Cavedo, Marie-Odile Habert, Hugo Bertin, Maxime Locatelli, Stephane Lehéricy, Bruno Dubois, Stefan J. Teipel, Harald Hampel
CLINICAL SIGNIFICANCE OF IN-VIVO STAGING OF REGIONAL AMYLOID DEPOSITION IN SUBJECTIVE MEMORY COMPLAINERS
published pages: P1262-P1263, ISSN: 1552-5260, DOI: 10.1016/j.jalz.2018.06.1774
Alzheimer\'s & Dementia 14/7 2019-09-18
2019 Anitha Devadoss, Rhiannan Forsyth, Ryan Bigham, Hina Abbasi, Muhammad Ali, Zari Tehrani, Yufei Liu, Owen. J. Guy
Ultrathin Functional Polymer Modified Graphene for Enhanced Enzymatic Electrochemical Sensing
published pages: 16, ISSN: 2079-6374, DOI: 10.3390/bios9010016
Biosensors 9/1 2019-09-18
2019 Fatemah A. Sakr, Michel J. Grothe, Enrica Cavedo, Irina Jelistratova, Marie-Odile Habert, Martin Dyrba, Gabriel Gonzalez-Escamilla, Hugo Bertin, Maxime Locatelli, Stephane Lehericy, Stefan Teipel, Bruno Dubois, Harald Hampel
Applicability of in vivo staging of regional amyloid burden in a cognitively normal cohort with subjective memory complaints: the INSIGHT-preAD study
published pages: , ISSN: 1758-9193, DOI: 10.1186/s13195-019-0466-3
Alzheimer\'s Research & Therapy 11/1 2019-09-18
2018 Kamrul Islam, Samar Damiati, Jagriti Sethi, Ahmed Suhail, Genhua Pan
Development of a Label-Free Immunosensor for Clusterin Detection as an Alzheimer’s Biomarker
published pages: 308, ISSN: 1424-8220, DOI: 10.3390/s18010308
Sensors 18/1 2019-09-18

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "BBDIAG" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "BBDIAG" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.1.)

GREAT (2019)

Grating Reflectors Enabled laser Applications and Training

Read More  

I-DireCT (2019)

Immune DIREcted and Cancer-selective immunoTherapy

Read More  

LongActNow (2019)

Long Acting Medicines for Complex Therapeutics Needed Now

Read More